Develops immunotherapies for cancer and infectious diseases.
Dec 2025Revenue $9.68M/yrExpenses $120M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will Precigen be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $9.68M and expenses $120M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $9.68M | $120M | −$111M |
| Dec 2024 | $3.92M | $139M | −$135M |
| Dec 2023 | $6.22M | $106M | −$99.8M |
| Dec 2018 | $151M | $657M | −$506M |
| Dec 2017 | $219M | $357M | −$138M |
| Dec 2016 | $191M | $316M | −$125M |
| Dec 2015 | $174M | $320M | −$147M |
| Dec 2014 | $71.9M | $142M | −$70.0M |
| Dec 2013 | $23.8M | $81.8M | −$58.0M |
| Dec 2012 | $13.8M | $88.9M | −$75.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.